Methods and compositions for diagnosis and prognosis of renal injury and renal failure
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Insulin-like growth factor-binding protein 2, Insulin-like growth factor-binding protein 3, Insulinlike growth factor-binding protein 4, and Insulin like growth factor-binding protein 6 as diagnostic and prognostic biomarker assays in renal injuries.
1. A method comprising:
(a) obtaining a body fluid sample from a subject having a persistent RIFLE I acute kidney injury or a persistent RIFLE F acute kidney injury; and
(b) detecting a level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the sample,
wherein the persistent RIFLE I acute kidney injury is an acute kidney injury for a period of 48 hours or more at a minimum RIFLE stage of RIFLE stage I, and
wherein the persistent RIFLE F acute kidney injury is an acute kidney injury for a period of 48 hours or more at a minimum RIFLE stage of RIFLE stage F.
2. The method of claim 1 , wherein the sample has an elevated level of the one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 as compared to a predetermined threshold level.
3. The method of claim 1 , wherein the detecting comprises contacting all or a portion of the sample with a binding reagent which binds to the one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6, and generating an assay result indicative of binding of the one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6.
4. The method of claim 3 , wherein the assay result is a measured concentration of the one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6.
5. The method of claim 4 , wherein the assay result is a composite of a plurality of assay results.
6. The method of claim 3 , wherein the binding reagent is an antibody.
7. The method of claim 1 , further comprising treating the subject for the persistent RIFLE I acute kidney injury or the persistent RIFLE F acute kidney injury.
8. The method of claim 1 , further comprising administering renal replacement therapy to the subject having the persistent RIFLE I acute kidney injury or the persistent RIFLE F acute kidney injury.
9. The method of claim 8 , wherein the renal replacement therapy comprises one or more of hemodialysis, peritoneal dialysis, hemofiltration, and renal transplantation.
10. The method of claim 1 , wherein the subject has the persistent RIFLE F acute kidney injury.
11. The method of claim 1 , wherein the subject has the persistent RIFLE I acute kidney injury.
12. The method of claim 1 , wherein the body fluid sample is a urine sample.
13. A method of treating acute kidney injury comprising:
(a) obtaining a urine sample from a subject;
(b) detecting a level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the urine sample;
(c) determining that the subject is at increased risk of future persistence of a RIFLE I acute kidney injury or future persistence of a RIFLE F acute kidney injury based on the level of one or more of insulin-like growth factor-binding protein 2, insulin-like growth factor-binding protein 3, insulin-like growth factor-binding protein 4, and insulin-like growth factor-binding protein 6 in the urine sample, and
(d) administering renal replacement therapy to the subject at the increased risk of future persistence of the RIFLE I acute kidney injury or future persistence of the RIFLE F acute kidney injury.
14. The method of claim 13 , wherein the renal replacement therapy comprises one or more of hemodialysis, peritoneal dialysis, hemofiltration, and renal transplantation.
15. The method of claim 13 , wherein the subject is determined to have an increased likelihood of the future persistence of the RIFLE I acute kidney injury or the future persistence of the RIFLE F acute kidney injury for 72 hours after the time the urine sample is obtained from the subject.
16. The method of claim 13 , wherein the future persistence comprises a persistence period that starts 72 hours after the sample is obtained.